Affordable Access

Publisher Website

Use of antipsychotics in the treatment of major depressive disorder in an outpatient mental health center

Authors
Journal
Annals of General Psychiatry
1744-859X
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Volume
9
Identifiers
DOI: 10.1186/1744-859x-9-s1-s169
Keywords
  • Meeting Abstract
Disciplines
  • Biology
  • Medicine
  • Pharmacology
  • Psychology

Abstract

Use of antipsychotics in the treatment of major depressive disorder in an outpatient mental health center MEETING ABSTRACT Open Access Use of antipsychotics in the treatment of major depressive disorder in an outpatient mental health center Carolina Garnier*, Juan Castaño, Patricia Alvaro, Rosa Sanchis, David Corcoles, Angeles Malagon, Belen Diaz, Luis Miguel Martin, Antoni Bulbena From 1st International Congress on Neurobiology and Clinical Psychopharmacology and European Psychiatric Association Conference on Treatment Guidance Thessaloniki, Greece. 19-22 November 2009 Background Antidepressants are currently the mainstay of treatment for depression; however, almost two thirds of patients will fail to achieve remission with initial treatment. Evi- dence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial anti- depressant effects in the absence of psychotic symptoms [1]. Materials and methods Using a sample of 100 patients with MDD who have been visited in Barcelona’s Sant Martí Sud outpatient mental health center during the year 2008, sociodemo- graphical (gender, age) and clinical data (toxic consume, psychiatric background, use of antipsychotics) are ana- lysed with SPSS 15.0 statistical package Results Antipsychotics are used in 27% of the patients, with a predominancy in the female gender (77.8%), a global average age of 57.9 ± 12.6 years. There is a predomi- nancy of absence of psychiatric background (55.6%) and the absence of previous hospitalisations (66.7%). In 96.3% of the sample there was no toxic abuse. It is observed the following distribution in the use of antipsychotics: quetiapine and olanzapine (29.6% each one), risperidone (26%), paliperidone (3%). Average dose was 5.7 mg/d for olanzapine, 2.3 mg/d for risperidone, 84.5 mg/d for quetiapine and 6 mg/d for paliperidone. Conclusions It is observed an important frequency in the use of anti- psychotic treatment for MDD, in relation with the fact that there is growing e

There are no comments yet on this publication. Be the first to share your thoughts.